as well as pharmacologically acceptable salts, where X independently denotes a heteroatom selected from O, S or an NH group which forms a five-member heteroarene condensed with an anthracenedione nucleus at bonds 2-3; n independently denotes a number from 2 to 4, which is equal to the number of spacer CH2 groups which link amino groups in peri-positions of heteroarene anthracenedione with nitrogen atoms of guanidine group residues located in side chains; m independently denotes a number from 2 to 4, which is equal to the number of spacer CH2 groups which link the nitrogen atom of a carboxamide group located at position 2 of the heterocyclic nucleus of heteroarene anthracenedione with the nitrogen atom of the guanidine group residue located in the side chain.;EFFECT: obtaining novel compounds which can be used in medicine for therapy of cancerous diseases.;2 tbl, 2 dwg, 8 ex"/>
公开/公告号RU2527459C1
专利类型
公开/公告日2014-08-27
原文格式PDF
申请/专利号RU20130113321
发明设计人 SHCHEKOTIKHIN ANDREJ EGOROVICH;TIKHOMIROV ALEKSANDR SERGEEVICH;SHCHELKINA ANNA KIRILLOVNA;SHTIL ALEKSANDR ALBERTOVICH;LIVSHITS MIKHAIL ARONOVICH;TSVETKOV VLADIMIR BORISOVICH;BORISOVA OLGA FILIPPOVNA;PREOBRAZHENSKAJA MARIJA NIKOLAEVNA;ILINSKIJ NIKOLAJ SERGEEVICH;MALJUTINA NATALJA MIKHAJLOVNA;KALJUZHNYJ DMITRIJ NIKOLAEVICH;DEZHENKOVA LJUBOV GEORGIEVNA;BYCHKOVA ELENA NIKOLAEVNA;
申请日2013-03-27
分类号C07D307/77;C07D333/50;A61K31/381;A61K31/343;A61P35/00;
国家 RU
入库时间 2022-08-21 15:38:20